Biocon

Buy Biocon With Target Of Rs 394

Buy Biocon With Target Of Rs 394Technical analyst D Prasad maintained 'buy' rating on Biocon Industries Limited stock to achieve a target of Rs 394.

According to analyst, the stock can be purchased above Rs 381 with a stop loss of Rs 373.

The stock of the company, on January 19, closed at Rs 377.50 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 464.60 and a low of Rs 256 on BSE.

Current EPS & P/E ratio stood at 16.37 and 23.70 respectively.

Biocon has announced its outcomes for the three month period ended December 2010.

Buy Biocon With Stop Loss Of Rs 340

Buy Biocon With Stop Loss Of Rs 340Stock market analyst Salil Sharma has maintained 'buy' rating on Biocon Ltd stock with a target of Rs 354

According to analyst, the interested investors can buy the stock with stop loss of Rs 340.

The stock of the company, on Sep 03, closed at Rs 345.50 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 356 and a low of Rs 230 on BSE.

Current EPS & P/E ratio stood at 15.62 and 22.22 respectively.

Biocon Q1 Net Up 33%

Biocon Q1 Net Up 33%Biocon has recorded a net profit of Rs 77 crore for April-June quarter of this fiscal (20010-11), recording year-on-year (YoY) expansion of 33%as against Rs 58 crore in the same period of last year.

In a regulatory filing, the top biotechnology firm stated that its total income grew by 33%YoY to Rs 672 crore for the three month period ended June 2010 as against Rs 505 crore during the same period of 2009-10.

The company's EBITDA (earnings before interest, taxes, depreciation and amortization) at Rs. 141 crore grew 27 percent YoY from Rs. 111 crore year ago.

Short Term Buy Call For RIL

Short Term Buy Call For RILStock market analyst Salil Sharma is of the view that investors can 'buy' Reliance India Ltd stock with a short term target of Rs 1060.

According to analyst, the investors can buy the stock with stop loss of Rs 1035.

Today, the stock of the company opened at Rs 1045 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 1186.15 and a low of Rs 875.50 on BSE.

Current EPS & P/E ratio stood at 49.31 and 21.01 respectively.

RIL has paid approx Rs 12,382 crore of unsecured loans during the last fiscal, lessening its arrears by about 15.5%.

Biocon’s fourth quarter profit zooms to Rs 81 crore

Biocon’s fourth quarter profit zooms to Rs 81 croreThe leading Biotechnology firm of India, Biocon has announced it's fourth quarter financial results. Biocon is basically known for its outlined services on diabetes, cancer and auto-immune diseases etc. The Bio firm has managed to register an impressive net profit. The company has made a profit of Rs 80.6 crore in this quarter.

During January to March this year the net profit has raised sharply as there was a huge increases in revenue. There was a forex loss of Rs 41.4 crore as well.

Buy Biocon With Stoploss Of Rs 289

Sell Biocon With Stoploss Of Rs 257Stock market analysts have maintained 'buy' rating on Biocon Ltd with an intraday target of Rs 299.

According to them, interested traders can purchase the stock with a strict stop loss of Rs 289.

If the bourses remain on the positive track, then the stock price will hit a target above Rs 305.

Shares of the company, on Wednesday (Dec 09), closed at Rs 293.20 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 298.40 and a low of Rs 90.10 on BSE.

Breast cancer Is Easily Curable: Biocon Chairperson Kiran Mazumdar

Breast cancer Biocon Chairperson Kiran Mazumdar Shaw told people not to be afraid of breast cancer even though its prevalence has been developing.

She added that breast cancer was no more a killer disease, and was curable without any difficulty.

Mazumdar was speaking on the opening of the Mazumdar Shaw Cancer Centre's 30-day long programme that was launched to make people aware about the need for an early detection via medical examinations.

She also said that a decade ago, carcinoma was known as a killer disease, but not anymore.

Sell Biocon With Stoploss Of Rs 257

Sell Biocon With Stoploss Of Rs 257Stock market analysts are of the view that investors can sell Biocon Ltd stock with a target price between Rs 250-245.

According to them, investors can sell the stock below Rs 253 with a strict stop loss of Rs 257.

If the stock fell below Rs 240, it may see more weakness.

Today (Oct 28), the stock opened at Rs 256 on the Bombay Stock Exchange (BSE). Current EPS & P/E ratio stood at 7.91 and 32.49 respectively. The share price has seen a 52-week high of Rs 284.40 and a low of Rs 86.55 on BSE.

Biocon's second quarter net at $13.85 mn

Biocon's second quarter net at $13.85 mnMumbai, Oct 22 : Bangalore-based biotech major Biocon posted a net profit of $13.85 million (Rs. 62.36 crore) in the quarter ended Sep 30 compared to $7.45 million (Rs. 33.5 crore) earned in the like period of the previous year, the company said in a filing Thursday.

The company's total income increased to $6.96 million (Rs. 312.44 crore) in the period under review from $59.6 million (Rs. 268 crore) during the corresponding quarter last year, Biocon told the Bombay Stock Exchange in a regulatory statement.

Gulf Oil enters into agreement with Biocon to sell pharmaceutical biz

BioconGulf Oil Corporation, leading Hinduja Group Company, has announced that its arm known as IDL Speciality Chemicals has inked a contract with Biocon.

Under the contract, IDL Speciality Chemicals will market its Active Pharmaceuticals Ingredients (API) undertaking.

The financial details of the contract have not been revealed by the company. API is the basic raw material which is utilized in making medicines.     

Gulf Oil Corporation is basically a lubricant company, which also engages in explosives, consult dealing in mining as well as infrastructure contracts, specialty chemicals dealing in bulk drugs and pharmaceutical sector.

Biocon inks ‘Exclusive Agreement’ with Amylin Pharmaceuticals

Biocon inks ‘Exclusive Agreement’ with Amylin PharmaceuticalsBiocon has informed that the company has signed an exclusive agreement with Amylin Pharmaceuticals to jointly develop, commercialize and manufacture a novel Peptide Hybrid drug to be used for treatment of Diabetes.

According to an official communiqué,  Amylin and Biocon would collaborate to develop the therapeutic potential of the compound and share development costs.    

Biocon Q1 net profit jumps four-fold at Rs 57 crore

Biocon Q1 net profit jumps four-fold at Rs 57 croreBiocon Ltd, a leading Bangalore-based biotechnology firm has reported four-fold jump in its consolidated net profit at Rs 57 crore for the quarter ended June 30, 2009 against Rs 15 crore in the same period ended June 2008.

Company's total income in the reporting quarter increased to Rs 505 crore from Rs 276 crore in the same quarter previous fiscal.

On a standalone basis, the company has clocked a net profit of Rs 47 crore up 58.44% during quarter under review as compared to Rs 30 crore in the same period last fiscal.

Biocon signs partnership deal with Mylan

Biocon signs partnership deal with MylanThe Rs 1,673-crore Bangalore-based biotech major, Biocon Limited, has signed a deal with US based Mylan Inc to collaborate in the field of generic biologic drugs. Both the firms will join hands for developing, manufacturing and commercializing biological compounds to achieve a leading position in the emerging generic drug industry, by virtue of their highly complementary capabilities in their respective domains.

Buy Biocon For Target Rs 265: Ashwani Gujral

BioconStock market analyst Ashwani Gujral has maintained ‘Buy’ rating on Biocon to achieve a target between Rs 260- Rs 265 in 1-2 trading sessions.

According to Mr. Gujral, interested traders can buy the stock with a strict stop loss of Rs 210.

Shares of the company, on Friday (June 26), closed at Rs 226.75 on the Bombay Stock Exchange (BSE). Current EPS & P/E ratio stood at 5.59 and 41.70 respectively. The share price has seen a 52-week high of Rs 234.70 and a low of Rs 86.55 on BSE.

Syndicate content